DE602006018822D1 - Verwendung des Agomelatins zur Herstellung eines Medikamentes zur Behandlung der bipolaren Erkrankungen - Google Patents

Verwendung des Agomelatins zur Herstellung eines Medikamentes zur Behandlung der bipolaren Erkrankungen

Info

Publication number
DE602006018822D1
DE602006018822D1 DE602006018822T DE602006018822T DE602006018822D1 DE 602006018822 D1 DE602006018822 D1 DE 602006018822D1 DE 602006018822 T DE602006018822 T DE 602006018822T DE 602006018822 T DE602006018822 T DE 602006018822T DE 602006018822 D1 DE602006018822 D1 DE 602006018822D1
Authority
DE
Germany
Prior art keywords
agomelatine
medicament
manufacture
treatment
bipolar disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006018822T
Other languages
English (en)
Inventor
Bodinat Christian De
Elisabeth Mocaer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35311309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602006018822(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratoires Servier SAS filed Critical Laboratoires Servier SAS
Publication of DE602006018822D1 publication Critical patent/DE602006018822D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
DE602006018822T 2005-04-20 2006-04-19 Verwendung des Agomelatins zur Herstellung eines Medikamentes zur Behandlung der bipolaren Erkrankungen Active DE602006018822D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0503937A FR2884714B1 (fr) 2005-04-20 2005-04-20 Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires

Publications (1)

Publication Number Publication Date
DE602006018822D1 true DE602006018822D1 (de) 2011-01-27

Family

ID=35311309

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006018822T Active DE602006018822D1 (de) 2005-04-20 2006-04-19 Verwendung des Agomelatins zur Herstellung eines Medikamentes zur Behandlung der bipolaren Erkrankungen

Country Status (41)

Country Link
US (1) US7947743B2 (de)
EP (1) EP1714647B1 (de)
JP (2) JP4580364B2 (de)
KR (2) KR100835451B1 (de)
CN (2) CN102038669A (de)
AP (1) AP2656A (de)
AR (1) AR057277A1 (de)
AT (1) ATE491443T1 (de)
AU (1) AU2006201655B2 (de)
BR (1) BRPI0601285A8 (de)
CA (1) CA2544136C (de)
CR (1) CR9426A (de)
CY (1) CY1111257T1 (de)
DE (1) DE602006018822D1 (de)
DK (1) DK1714647T3 (de)
EA (1) EA013462B1 (de)
ES (1) ES2357901T3 (de)
FR (1) FR2884714B1 (de)
GE (1) GEP20094651B (de)
GT (1) GT200600141A (de)
HK (1) HK1093906A1 (de)
HR (1) HRP20110083T1 (de)
IL (1) IL186373A (de)
JO (1) JO2666B1 (de)
MA (1) MA28266A1 (de)
ME (1) ME01951B (de)
MY (1) MY143171A (de)
NO (1) NO336010B1 (de)
NZ (1) NZ546630A (de)
PE (1) PE20061337A1 (de)
PL (1) PL1714647T3 (de)
PT (1) PT1714647E (de)
RS (1) RS51659B (de)
SG (1) SG126868A1 (de)
SI (1) SI1714647T1 (de)
TN (1) TNSN07364A1 (de)
TW (2) TW200940049A (de)
UA (1) UA83681C2 (de)
UY (1) UY29470A1 (de)
WO (1) WO2006111653A1 (de)
ZA (1) ZA200603160B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2890563B1 (fr) * 2005-09-09 2007-10-19 Servier Lab Nouvelle association entre l'agomelatine et un agent thymoregulateur et les compositions pharmaceutiques qui la contiennent
AU2008247805A1 (en) * 2007-05-01 2008-11-13 Concert Pharmaceuticals Inc. Naphthyl(ethyl) acetamides
FR2978916B1 (fr) * 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
EP2856934A1 (de) * 2013-10-04 2015-04-08 Les Laboratoires Servier Biomarker zur Vorhersage der langfristigen Remission bei Depression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5585118A (en) * 1995-06-02 1996-12-17 Brigham And Women's Hospital Choline in the treatment of bipolar disorder
RS50680B (sr) * 2001-02-27 2010-06-30 Ortho-Mcneil Pharmaceutical Inc. Karbamatna jedinjenja za upotrebu u sprečavanju i lečenju bipolarnih poremećaja
FR2834890B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
JP2007517040A (ja) * 2003-12-24 2007-06-28 セプレイコー インコーポレイテッド 睡眠の質を改善するためのメラトニン併用療法

Also Published As

Publication number Publication date
HRP20110083T1 (hr) 2011-03-31
EP1714647B1 (de) 2010-12-15
HK1093906A1 (en) 2007-03-16
JO2666B1 (en) 2012-06-17
US20060240127A1 (en) 2006-10-26
UA83681C2 (uk) 2008-08-11
AU2006201655B2 (en) 2009-04-23
ES2357901T3 (es) 2011-05-03
CR9426A (es) 2008-02-21
IL186373A0 (en) 2008-08-07
GT200600141A (es) 2006-11-22
EA200600600A1 (ru) 2006-10-27
BRPI0601285A (pt) 2006-12-19
KR100835451B1 (ko) 2008-06-09
GEP20094651B (en) 2009-03-25
JP2010280699A (ja) 2010-12-16
CA2544136C (fr) 2012-02-21
MY143171A (en) 2011-03-31
ATE491443T1 (de) 2011-01-15
JP4580364B2 (ja) 2010-11-10
JP5341037B2 (ja) 2013-11-13
BRPI0601285A8 (pt) 2021-03-30
SI1714647T1 (sl) 2011-03-31
TW200940049A (en) 2009-10-01
EP1714647A1 (de) 2006-10-25
RS51659B (en) 2011-10-31
ME01951B (de) 2011-10-31
SG126868A1 (en) 2006-11-29
PT1714647E (pt) 2011-01-14
NO336010B1 (no) 2015-04-20
CN1853619B (zh) 2011-02-02
US7947743B2 (en) 2011-05-24
JP2006316056A (ja) 2006-11-24
PL1714647T3 (pl) 2011-05-31
TW200716083A (en) 2007-05-01
MA28266A1 (fr) 2006-11-01
NZ546630A (en) 2007-09-28
ZA200603160B (en) 2007-06-27
CA2544136A1 (fr) 2006-10-20
AU2006201655A1 (en) 2006-11-09
AR057277A1 (es) 2007-11-28
TWI318115B (en) 2009-12-11
CN102038669A (zh) 2011-05-04
FR2884714A1 (fr) 2006-10-27
TNSN07364A1 (en) 2008-12-31
CN1853619A (zh) 2006-11-01
AP2007004212A0 (en) 2007-10-31
KR20080028389A (ko) 2008-03-31
NO20061705L (no) 2006-10-23
DK1714647T3 (da) 2011-03-07
AP2656A (en) 2013-05-07
KR20060110803A (ko) 2006-10-25
WO2006111653A1 (fr) 2006-10-26
CY1111257T1 (el) 2015-08-05
UY29470A1 (es) 2006-05-31
FR2884714B1 (fr) 2011-05-06
EA013462B1 (ru) 2010-04-30
IL186373A (en) 2012-06-28
PE20061337A1 (es) 2007-01-27

Similar Documents

Publication Publication Date Title
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE512661T1 (de) Verwendung eines betablockers zur herstellung eines arzneimittels zur behandlung von hämangiomen
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
ATE390407T1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
ATE540941T1 (de) 1-ä2-(2,4-dimethylphenylsulfanyl)phenylüpiperaz n als verbindung mit kombinierter serotoninwiederaufnahme-, 5-ht3- und 5-ht1a- aktivität zur behandlung kognitiver störungen
ATE517085T1 (de) Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
DE602006019560D1 (de) 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
DE602007008494D1 (de) Verwendung von Agomelatin zur Herstellung von Medikamenten zur Behandlung der generalisierten Angststörung
ATE482709T1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen
DE602006015387D1 (de) Beta-2 Adrenoceptor Agonisten zur Behandlung von Bindegewebserkrankungen der Haut
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
ZA200607531B (en) Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient
ATE510536T1 (de) Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen
DE502006008804D1 (de) Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken
DE602006018822D1 (de) Verwendung des Agomelatins zur Herstellung eines Medikamentes zur Behandlung der bipolaren Erkrankungen
DE60318327D1 (de) Verwendung von resveratrol zur herstellung eines arzneimittels zur behandlung von grippe
DE602005000442D1 (de) Verwendung von alpha-1-Antitrypsin zur Herstellung eines Medikaments zur Behandlung von Fibromyalgie
DE602007013166D1 (de) Einsatz von Agomelatin zur Herstellung von Medikamenten zur Behandlung des Smith-Magenis-Syndroms (SMS)
ATE446757T1 (de) 1-ä2h-1-benzopyran-2-one-8-ylü- piperazinderivative zur behandlung von bewegungsstörungen